Skip to main content

Table 2 Baseline characteristics of analysis group

From: PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma

Variables Analysis group HCC patients with PVTT Controls P value
Sex F/M 9/64 4/17 5/47 0.27
Age (years) 57.88 ± 10.03 55.33 ± 9.62 58.90 ± 10.10 0.17
ALT 27 (10–261.1) 39 (10–147) 24.5 (10–261.1) 0.97
AST 38 (13–291) 47 (13–105) 36.5 (17–291) 0.38
TBiL 17.8 (8.5–457) 22.4 (9.4–407.9) 17.35 (8.5–457.0) 0.26
ALB 36.98 ± 4.78 35.96 ± 4.27 37.39 ± 4.96 0.25
D-Dimer (mg/L) 1.1 (0.27–15.61) 2.12 (0.27–15.61) 0.56 (0.10–13.95) 0.001
PTA 82.31 ± 12.92 79.84 ± 11.34 83.31 ± 13.48 0.30
PLT (×109/L) 161.96 ± 102.87 173.57 ± 118.47 157.27 ± 96.73 0.54
AFP 393.09 (1.33–1210.0) 469.17(3.10–1210) 362.36 (1.7–1210) 0.21
PIVKA-II (mAU/ml) 196.12 (12–75,000.00) 995.8 (12–75,000.00) 94.87 (13–70,997.0) 0.003
Child-Pugh class
 A 37 9 28 0.45
 B 36 12 24  
 HBsAg (COI) 4512 (12.2–7542.0) 5067.0 (62.33–7070.0) 4106 (12.2–7542.0) 0.35
HBeAg
 Positive 32 11 21 0.43
 Negative 41 10 31  
 HBV-DNA 5800.0 (0.0–4.16x107) 4800.0 (0.0–2.99x106) 6285.0 (0.0–4.16x107) 0.81